Table 2. Top pathways with affected genes altered by Cebpa knockdown*.
Pathway | −logP | R | Genes |
Production of NOand reactive O2 inmacrophages | 4.74 | 0.076 | MAP3K11,MAP3K6,MPO,IKBKE,IFNGR1,TLR4,NFKBIA, RHOB, RND3,CYBA,RHOU,S100A8,TNF,MAP3K3,SIRPA,PRKCB |
Interleukin-10signaling | 3.43 | 0.103 | NFKBIA,FCGR2A,BLVRB,IL1B,IKBKE,LBP, FCGR2B,TNF |
LPS/IL-1mediatedinhibition of RXRfunction | 3.20 | 0.063 | ALDH4A1,MGST1,GSTM5,CHST12,PAPSS2,TLR4,HS6ST1,MGST2, IL1B, ALAS1,ALDH3B1,LBP,CHST13,TNF,ACSL1 |
Inhibitor of NOsynthase (iNOS)signaling | 3.04 | 0.113 | TLR4,NFKBIA,IKBKE,IFNGR1,LBP,IRAK3 |
Aryl hydrocarbonreceptor signaling | 2.99 | 0.068 | TGM2,ALDH4A1,MGST1,MGST2,GSTM5,CDKN1A,IL1B,ALDH3B1, CCND1,TNF,NFE2L2 |
Interleukin-8signaling | 2.97 | 0.064 | VCAM1,NRAS,ANGPT1,MPO,IKBKE,IRAK3,CCND1, PLD1,CSTB, RND3,RHOB,RHOU,PRKCB |
Hepatocytegrowth factorsignaling | 2.96 | 0.086 | ETS1,NRAS,MAP3K11,MAP3K6,HGF,CDKN1A,CCND1, MAP3K3,PRKCB |
CD27 signaling inlymphocytes | 2.70 | 0.105 | NFKBIA,MAP3K11,MAP3K6,IKBKE, CD27,MAP3K3 |
B cell receptorsignaling | 2.66 | 0.067 | ETS1,NRAS,NFKBIA,MAP3K11,MAP3K6,FCGR2A,PIK3AP1,IKB KE, FCGR2B,MAP3K3,PRKCB |
High mobilitygroup box 1(HMGB1)signaling | 2.54 | 0.081 | TLR4,VCAM1,NRAS,RND3,RHOB,RHOU,IFNGR1,TNF |
Xenobioticmetabolismsignaling | 2.48 | 0.054 | ALDH4A1,MGST1,MAP3K11,NRAS,MAP3K6,GSTM5,CHST12, HS6ST1,MGST2,IL1B,ALDH3B1,CHST13,NFE2L2,TNF,MAP3K3, PRKCB |
Cholinebiosynthesis | 2.39 | 0.136 | PCYT1B,CHPT1,PLD1 |
Vitamin DReceptor/RXRactivation | 2.38 | 0.086 | SERPINB1,SPP1,CAMP,GADD45A,CDKN1A, CEBPA,PRKCB |
TREM1 signaling | 2.38 | 0.085 | TLR4,LAT2,MPO,IL1B,FCGR2B,TNF |
TNFR2 signaling | 2.25 | 0.121 | TANK,NFKBIA,IKBKE,TNF |
PI-3-kinasesignaling in Blymphocytes | 2.20 | 0.064 | TLR4,NRAS,C3,NFKBIA,ATF5,PIK3AP1, IKBKE,FCGR2B,PRKCB |
*Top pathways from analysis of RNAs with >1.5-fold change in 2 experiments, with affected genes listed and ordered by –logP values. R values, indicating the proportion of genes in a pathway affected by Cebpa knockdown, are also shown.